Form 4: Minerva Neurosciences Director Receives Stock Options

Director Fouzia Laghrissi-Thode was granted 50,000 stock options in Minerva Neurosciences, Inc. as part of a standard equity incentive.

Summary

• Director Fouzia Laghrissi-Thode received a grant of 50,000 stock options on June 3, 2026.
• The options have an exercise price of $4.68 per share.
• The options are set to expire on June 2, 2036.
• Vesting occurs in four equal quarterly installments starting three months after the grant date, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• The value of the options is dependent on the future market performance of the company's common stock.

Future Outlook

The options vest over a one-year period, incentivizing the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant of 50,000 options is consistent with typical equity compensation packages for non-employee directors in small-cap biopharmaceutical companies.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of the first 12,500 options scheduled for September 2026.

Key Dates

Keywords

Minerva Neurosciences, NERV, Form 4, Director Compensation, Stock Options, Insider Transaction